B. 1. Angelo, E. Prat, and J. , Uterine sarcomas: A review, Gynecologic Oncology, vol.116, issue.1, pp.131-140, 2010.
DOI : 10.1016/j.ygyno.2009.09.023

S. Pecorelli, Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium, International Journal of Gynecology & Obstetrics, vol.105, issue.2, pp.103-107, 2009.
DOI : 10.1016/j.ijgo.2009.02.012

G. Artioli, J. Wabersich, K. Ludwig, M. Gardiman, L. Borgato et al., Rare uterine cancer: Carcinosarcomas. Review from histology to treatment, Critical Reviews in Oncology/Hematology, vol.94, issue.1, pp.98-104, 2010.
DOI : 10.1016/j.critrevonc.2014.10.013

. Hadoux, Léiomyosarcomes utérins : épidémiologie, histologie, biologie, diagnostic, pronostic et traitement, Bulletin du cancer. sept, pp.903-918, 2013.

F. Major, J. Blessing, S. Silverberg, C. Morrow, W. Creasman et al., Prognostic factors in early-stage uterine sarcoma: A gynecologic oncology group study, Cancer, vol.34, issue.S4, 1993.
DOI : 10.1002/cncr.2820710440

K. Tse, R. Crawford, and H. Ngan, Staging of uterine sarcomas, Best Practice & Research Clinical Obstetrics & Gynaecology, vol.25, issue.6, pp.733-782, 2011.
DOI : 10.1016/j.bpobgyn.2011.05.011

S. Kurihara, Y. Oda, Y. Ohishi, A. Iwasa, T. Takahira et al., Endometrial Stromal Sarcomas and Related High-grade Sarcomas: Immunohistochemical and Molecular Genetic Study of 31 Cases, The American Journal of Surgical Pathology, vol.32, issue.8, pp.1228-1266, 2008.
DOI : 10.1097/PAS.0b013e31816a3b42

M. Nucci, D. Harburger, J. Koontz, P. Dal-cin, and J. Sklar, Molecular Analysis of the JAZF1-JJAZ1 Gene Fusion by RT-PCR and Fluorescence In Situ Hybridization in Endometrial Stromal Neoplasms, The American Journal of Surgical Pathology, vol.31, issue.1, pp.65-70, 2007.
DOI : 10.1097/01.pas.0000213327.86992.d1

S. Chiang, R. Ali, N. Melnyk, J. Mcalpine, D. Huntsman et al., Frequency of Known Gene Rearrangements in Endometrial Stromal Tumors, The American Journal of Surgical Pathology, vol.35, issue.9, pp.1364-72, 2011.
DOI : 10.1097/PAS.0b013e3182262743

P. Pautier, E. Nam, D. Provencher, A. Hamilton, G. Mangili et al., Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus, International Journal of Gynecological Cancer, vol.24, issue.9, pp.73-77, 2014.
DOI : 10.1097/IGC.0000000000000281

P. Pautier, C. Genestie, A. Rey, P. Morice, B. Roche et al., Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma, Cancer. 15 mars, vol.88, issue.6, pp.1425-1456, 2000.

M. Pelmus, F. Penault-llorca, L. Guillou, C. F. Bertrand, G. Trassard et al., Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus, International Journal of Gynecological Cancer, vol.62, issue.3, pp.385-90, 2009.
DOI : 10.1111/IGC.0b013e3181a1bfbc

T. Niemann, S. Raab, J. Lenel, J. Rodgers, and R. Robinson, p53 protein overexpression in smooth muscle tumors of the uterus*1, Human Pathology, vol.26, issue.4, pp.375-384, 1995.
DOI : 10.1016/0046-8177(95)90136-1

K. Hall, M. Teneriello, R. Taylor, S. Lemon, M. Ebina et al., Analysis of Ki-ras, p53, and MDM2 Genes in Uterine Leiomyomas and Leiomyosarcomas, Gynecologic Oncology, vol.65, issue.2, pp.330-335, 1997.
DOI : 10.1006/gyno.1997.4653

R. Blom, C. Guerrieri, O. Stâl, H. Malmström, and E. Simonsen, Leiomyosarcoma of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 49 Cases, Gynecologic Oncology, vol.68, issue.1, pp.54-61, 1998.
DOI : 10.1006/gyno.1997.4889

S. Akhan, E. Yavuz, A. Tecer, C. Iyibozkurt, S. Topuz et al., The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study, Gynecologic Oncology, vol.99, issue.1, pp.36-42, 2005.
DOI : 10.1016/j.ygyno.2005.05.019

D. Angelo, E. Espinosa, I. Ali, R. Gilks, C. Rijn et al., Uterine leiomyosarcomas: Tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis, Gynecologic Oncology, vol.121, issue.2, pp.328-361, 2011.
DOI : 10.1016/j.ygyno.2011.01.022

F. Amant, A. Coosemans, M. Debiec-rychter, D. Timmerman, and I. Vergote, Clinical management of uterine sarcomas, The Lancet Oncology, vol.10, issue.12, pp.1188-98, 2009.
DOI : 10.1016/S1470-2045(09)70226-8

O. Zivanovic, L. Jacks, A. Iasonos, M. Leitao, R. Soslow et al., A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma, Cancer, vol.101, issue.suppl 1, pp.660-669, 2012.
DOI : 10.1002/cncr.26333

A. Iasonos, E. Keung, O. Zivanovic, R. Mancari, M. Peiretti et al., External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma, Cancer, vol.78, issue.10, pp.1816-1838, 2013.
DOI : 10.1002/cncr.27971

I. Chew and E. Oliva, Endometrial Stromal Sarcomas, Advances in Anatomic Pathology, vol.17, issue.2, pp.113-134, 2010.
DOI : 10.1097/PAP.0b013e3181cfb7c2

P. Morice, A. Rodrigues, P. Pautier, A. Rey, S. Camatte et al., Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure]. Gynécologie Obstétrique Fertil, févr, vol.31, issue.2, pp.147-50, 2003.

R. Giuntoli, D. Metzinger, C. Dimarco, S. Cha, J. Sloan et al., Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy???, Gynecologic Oncology, vol.89, issue.3, pp.460-469, 2003.
DOI : 10.1016/S0090-8258(03)00137-9

M. Leitao, Y. Sonoda, M. Brennan, R. Barakat, and D. Chi, Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus, Gynecologic Oncology, vol.91, issue.1, pp.209-221, 2003.
DOI : 10.1016/S0090-8258(03)00478-5

B. Goff, L. Rice, D. Fleischhacker, H. Muntz, S. Falkenberry et al., Uterine Leiomyosarcoma and Endometrial Stromal Sarcoma: Lymph Node Metastases and Sites of Recurrence, Gynecologic Oncology, vol.50, issue.1, pp.105-114, 1993.
DOI : 10.1006/gyno.1993.1172

D. Kapp, J. Shin, and J. Chan, Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas, Cancer, vol.92, issue.4, pp.820-850, 2008.
DOI : 10.1002/cncr.23245

J. Chan, N. Kawar, J. Shin, K. Osann, L. Chen et al., Endometrial stromal sarcoma: a population-based analysis, British Journal of Cancer, vol.106, issue.8, pp.1210-1215, 2008.
DOI : 10.3322/canjclin.46.2.113

J. Shah, C. Bryant, S. Kumar, R. Ali-fehmi, J. Malone et al., Lymphadenectomy and Ovarian Preservation in Low-Grade Endometrial Stromal Sarcoma, Obstetrics & Gynecology, vol.112, issue.5, pp.1102-1110, 2008.
DOI : 10.1097/AOG.0b013e31818aa89a

G. Garg, J. Shah, E. Toy, C. Bryant, S. Kumar et al., Stage IA vs. IB endometrial stromal sarcoma: Does the new staging system predict survival?, Gynecologic Oncology, vol.118, issue.1, pp.8-13, 2010.
DOI : 10.1016/j.ygyno.2010.04.008

J. Riopel, M. Plante, M. Renaud, M. Roy, and B. Têtu, Lymph node metastases in low-grade endometrial stromal sarcoma, Gynecologic Oncology, vol.96, issue.2, pp.402-408, 2005.
DOI : 10.1016/j.ygyno.2004.10.021

B. Barney, J. Tward, T. Skidmore, and D. Gaffney, Does Radiotherapy or Lymphadenectomy Improve Survival in Endometrial Stromal Sarcoma?, International Journal of Gynecological Cancer, vol.50, issue.7, pp.1232-1240, 2009.
DOI : 10.1111/IGC.0b013e3181b33c9a

O. Reich, R. Winter, and S. Regauer, Should lymphadenectomy be performed in patients with endometrial stromal sarcoma?, Gynecologic Oncology, vol.97, issue.3, pp.982-982, 2005.
DOI : 10.1016/j.ygyno.2005.01.034

J. Park, S. Park, D. Kim, J. Kim, Y. Kim et al., The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma, Gynecologic Oncology, vol.122, issue.2, pp.255-264, 2011.
DOI : 10.1016/j.ygyno.2011.04.021

S. Sampath, T. Schultheiss, J. Ryu, and J. Wong, The Role of Adjuvant Radiation in Uterine Sarcomas, International Journal of Radiation Oncology*Biology*Physics, vol.76, issue.3, pp.728-762, 2010.
DOI : 10.1016/j.ijrobp.2009.02.077

A. Gadducci, F. Landoni, E. Sartori, P. Zola, T. Maggino et al., Uterine Leiomyosarcoma: Analysis of Treatment Failures and Survival, Gynecologic Oncology, vol.62, issue.1, pp.25-32, 1996.
DOI : 10.1006/gyno.1996.0185

A. Gadducci, E. Sartori, F. Landoni, P. Zola, T. Maggino et al., Endometrial Stromal Sarcoma: Analysis of Treatment Failures and Survival, Gynecologic Oncology, vol.63, issue.2, pp.247-53, 1996.
DOI : 10.1006/gyno.1996.0314

C. Leath, W. Huh, J. Hyde, D. Cohn, K. Resnick et al., A multi-institutional review of outcomes of endometrial stromal sarcoma, Gynecologic Oncology, vol.105, issue.3, pp.630-634, 2007.
DOI : 10.1016/j.ygyno.2007.01.031

N. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), European Journal of Cancer, vol.44, issue.6, pp.808-826, 1990.
DOI : 10.1016/j.ejca.2008.01.019

A. Wolfson, M. Brady, T. Rocereto, R. Mannel, Y. Lee et al., A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I???IV carcinosarcoma (CS) of the uterus???, Gynecologic Oncology, vol.107, issue.2, pp.177-85, 2007.
DOI : 10.1016/j.ygyno.2007.07.070

S. Sampath and D. Gaffney, Role of radiotherapy treatment of uterine sarcoma, Best Practice & Research Clinical Obstetrics & Gynaecology, vol.25, issue.6, pp.761-72, 2011.
DOI : 10.1016/j.bpobgyn.2011.06.004

W. Small, L. Mell, P. Anderson, C. Creutzberg, D. Santos et al., Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.71, issue.2, pp.428-462, 2008.
DOI : 10.1016/j.ijrobp.2007.09.042

G. Omura, J. Blessing, F. Major, S. Lifshitz, C. Ehrlich et al., A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study., Journal of Clinical Oncology, vol.3, issue.9, pp.1240-1245, 1985.
DOI : 10.1200/JCO.1985.3.9.1240

P. Pautier, A. Floquet, L. Gladieff, E. Bompas, I. Ray-coquard et al., A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group, Annals of Oncology, vol.24, issue.4, pp.1099-104, 2013.
DOI : 10.1093/annonc/mds545

G. Omura, F. Major, J. Blessing, T. Sedlacek, J. Thigpen et al., A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas, Cancer, vol.3, issue.4, pp.626-658, 1983.
DOI : 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E

G. Sutton, J. Blessing, and J. Malfetano, Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group Study, Gynecologic Oncology, vol.62, issue.2, pp.226-235, 1996.
DOI : 10.1006/gyno.1996.0220

M. Hensley, J. Blessing, R. Mannel, and P. Rose, Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial, Gynecologic Oncology, vol.109, issue.3, pp.329-363, 2008.
DOI : 10.1016/j.ygyno.2008.03.010

B. Monk, J. Blessing, D. Street, C. Muller, J. Burke et al., A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study, Gynecologic Oncology, vol.124, issue.1, pp.48-52, 2012.
DOI : 10.1016/j.ygyno.2011.09.019

P. Pautier, A. Floquet, N. Penel, S. Piperno-neumann, N. Isambert et al., Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study), The Oncologist, vol.17, issue.9, pp.1213-1233, 2012.
DOI : 10.1634/theoncologist.2011-0467

O. Cearbhaill, R. Zhou, Q. Iasonos, A. Soslow, R. Leitao et al., Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors, Gynecologic Oncology, vol.116, issue.3, pp.424-433, 2010.
DOI : 10.1016/j.ygyno.2009.10.064

W. Van-der-graaf, J. Blay, S. Chawla, D. Kim, B. Bui-nguyen et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, vol.379, issue.9829, pp.1879-86, 2012.
DOI : 10.1016/S0140-6736(12)60651-5

M. Leitao, M. Brennan, M. Hensley, Y. Sonoda, A. Hummer et al., Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma, Gynecologic Oncology, vol.87, issue.3, pp.287-94, 2002.
DOI : 10.1006/gyno.2002.6840

N. Penel, A. Italiano, N. Isambert, E. Bompas, G. Bousquet et al., Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy, Annals of Oncology, vol.21, issue.6, pp.1361-1366, 2010.
DOI : 10.1093/annonc/mdp485

F. Ferrer, S. Sabater, B. Farrús, F. Guedea, A. Rovirosa et al., Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the GRUP ONCOLOGIC CATAL??-OCCIT??, International Journal of Radiation Oncology*Biology*Physics, vol.44, issue.1, pp.47-52, 1999.
DOI : 10.1016/S0360-3016(98)00515-X

O. Zivanovic, M. Leitao, A. Iasonos, L. Jacks, Q. Zhou et al., Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems, Journal of Clinical Oncology, vol.27, issue.12, pp.2066-72, 2009.
DOI : 10.1200/JCO.2008.19.8366

J. Prat, FIGO staging for uterine sarcomas, International Journal of Gynecology & Obstetrics, vol.112, issue.(4), pp.177-185, 2009.
DOI : 10.1016/j.ijgo.2008.12.008

F. Odicino, S. Pecorelli, L. Zigliani, and W. Creasman, History of the FIGO cancer staging system, International Journal of Gynecology & Obstetrics, vol.6, issue.(Suppl l), pp.205-215, 2008.
DOI : 10.1016/j.ijgo.2007.11.004

G. Garg, J. Shah, J. Liu, C. Bryant, S. Kumar et al., Validation of Tumor Size as Staging Variable in the Revised International Federation of Gynecology and Obstetrics Stage I Leiomyosarcoma, International Journal of Gynecological Cancer, vol.280, issue.7, pp.1201-1207, 2010.
DOI : 10.1111/IGC.0b013e3181e9d0ba

D. Chi, B. Mychalczak, P. Saigo, J. Rescigno, and C. Brown, The Role of Whole-Pelvic Irradiation in the Treatment of Early-Stage Uterine Carcinosarcoma, Gynecologic Oncology, vol.65, issue.3, pp.493-501, 1997.
DOI : 10.1006/gyno.1997.4676